Market Trends of Neuromyelitis Optica Spectrum Disorder Industry
Monoclonal Antibody Drugs Segment Expects to Register a High CAGR in the Forecast Period
- The monoclonal antibody drugs segment is expected to dominate the market due to its high efficacy and tolerability in treating autoimmune diseases, including neuromyelitis optica spectrum disorder. In this disorder, B cells produce auto-antibodies, secrete cytokines/chemokines, and interact with T cells, playing a pathogenic role. As a result, monoclonal antibody-mediated B cell depletion has emerged as a viable treatment option for NMOSD. Notable monoclonal antibody drugs for treating NMOSD include Rituximab, Inebilizumab, Tocilizumab, Satralizumab, and Eculizumab.
- Furthermore, the market growth is driven by the increasing approvals of monoclonal antibody drugs and the growing research and development activities by the industry players to develop more effective treatment options for patients with NMOSD.
- For instance, in November 2021, the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) authorized Horizon's UPLINZA as a monotherapy for treating adult patients with NMOSD who test positive for anti-aquaporin-4 immunoglobulin G (AQP4-IgG+) antibodies. Additionally, in June 2022, Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. received approval for Anti-CD20 Monoclonal Antibody Rituxan for preventing the recurrence of neuromyelitis optica spectrum disorder.
- In summary, the increasing efficacy and tolerability of monoclonal antibody drugs, rising product approvals, and research and development activities by the market players are driving the growth of this segment, which is expected to further propel the market growth over the forecast period.
Understand The Key Trends Shaping This Market
Download Sample
North America is Expected to Have the Significant Market Share
- North America holds a significant market share in the neuromyelitis optica spectrum disorder (NMOSD) treatment market, owing to several factors. One of the primary drivers of market growth in the region is the increasing incidence and prevalence of NMOSD. According to the National Center for Biotechnology Information, approximately 15,000 people in the United States were affected by this disorder in 2021.
- Additionally, the region's well-established healthcare infrastructure and availability of efficient treatment methods also contribute to the market growth. Moreover, non-profit organizations' financial assistance programs and increasing research and development activities in the region further support the growth of the market. For example, The Patient Access Network (PAN) Foundation launched a new financial assistance program in November 2021 to support individuals living with NMOSD.
- Furthermore, recent product approvals and increasing research and development activities in the region are also driving the market's growth. In May 2022, Alexion announced positive results for the open-label Phase III CHAMPION-NMOSD trial of ULTOMIRIS (ravulizumab-cwvz). The study showed a positive impact on relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD compared to the external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial.
- In conclusion, the increasing prevalence of NMOSD, rising research and development activities, and product approvals are expected to fuel the growth of the NMOSD treatment market in North America in the near future.
Get Analysis on Important Geographic Markets
Download Sample
